Legend Biotech Corporation (NASDAQ:LEGN) is one of the best healthcare stocks with the highest upside. J.P. Morgan analyst ...

JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

H.C. Wainwright lowered the firm’s price target on Legend Biotech (LEGN) to $60 from $75 and keeps a Buy rating on the shares. Johnson & Johnson ...

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

As another J&J department bites the dust, leadership is focused on what’s working in the pharma business, and there’s plenty ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson has undergone a significant transformation in recent years, particularly with the spin-off of its consumer health unit into Kenvue. This strategic move has allowed JNJ to concentrate ...

In a statement, Cabaletta CEO Steven Nichtberger, M.D., highlighted Gavel’s previous experience commercializing cell ...

Guidance was raised again, with operational sales growth midpoint moving to 5.1% (previous: 4.8%) and reported sales growth midpoint at 5.7% (previous: 5.4%), reflecting increased confidence in both ...

Reporting third quarter earnings on Tuesday, Johnson & Johnson CEO Joaquin Duato said the healthcare giant has not yet secured a drug pricing deal with the White House, but discussions are ongoing.

Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated ...

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion ...